A Phase 3 interventional study of Tamsulosin 0.2mg and Tadalafil 5mg in Benign Prostatic Hyperplasia and Erectile Dysfunction, sponsored by IlDong Pharmaceutical Co Ltd. Status unknown at 1 site in Korea, Republic of. Open to male participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2016-08-12.
Sponsored by IlDong Pharmaceutical Co Ltd · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies testing tamsulosin in Prostatic Hyperplasia — 8 open to participants now, 8 under way, 1 of them phase 3. Tamsulosin · Prostatic Hyperplasia.
Among the 48 studies testing tamsulosin in Prostatic Hyperplasia, this one is the 16th largest by planned enrollment, is one of 3 that started in 2016, is one of 11 in phase 3, and was the 31st registered.
828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.
Browse Prostatic Hyperplasia studies →8 of the 48 studies testing tamsulosin in Prostatic Hyperplasia are open now, in 3 countries. Recruiting first, the newest first:
Ain Shams University · Sites in Egypt
Ages 45+
Beni-Suef University · Sites in Egypt
Ages 50+ · Men only
Ankara Training and Research Hospital · Sites in Turkey
Ages 40–85 · Men only
Azienda Ospedaliero Universitaria Maggiore della Carita · Sites in Italy
Ages 40+ · Men only · Healthy volunteers
Il-Yang Pharm. Co., Ltd.
Ages 45+ · Men only
By country, each count listing its studies:
Tamsulosin: first FDA approval 1997 (FLOMAX). What it is approved for, and how studies give it, is on its page →
Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.
This study: 45 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 3 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 330 is above the median of 92 across 627 interventional studies indexed under Prostatic Hyperplasia.
Median enrollment 118 across the 48 interventional studies. Of the 35 that completed or were terminated, 12 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 48 have an industry lead sponsor. The 10 most frequent:
IlDong Pharmaceutical Co Ltd is the lead sponsor of 50 studies on the registry; 1 is open to participants now.
IlDong Pharmaceutical Co Ltd has 2 studies filed under Prostatic Hyperplasia — fewer than ten, so there is no comparison to draw.
5 of the studies testing tamsulosin in Prostatic Hyperplasia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07870759Phase 3Il-Yang Pharm. Co., Ltd.Efficacy and Safety of Combination Therapy Compared With Monotherapy in Patients With Benign Prostatic Hyperplasia | 2027-08-31 |
| NCT07722884Ain Shams UniversityTamsulosin Monotherapy Versus Combination Therapy With Tadalafil (2.5 mg vs 5 mg) in Managing Male LUTS Secondary to BPH | 2027-01-01 |
| NCT07743034Mohsen PouraziziIris Structural Changes With Tamsulosin vs. Silodosin in Benign Prostatic Hyperplasia Patients | 2027-04 |
| NCT07743060Mohsen PouraziziPupil Size and Choroidal Thickness Changes With Tamsulosin vs. Silodosin in Benign Prostatic Hyperplasia Patients | 2027-04 |
| NCT07650968Beni-Suef UniversityTamsulosin Dose Escalation or Silodosin Switch Before Trial Without Catheter in BPH-Related Acute Urinary Retention | 2027-05 |
Add all 5 to your calendar (.ics) → With an account.
Among the 48 studies testing tamsulosin in Prostatic Hyperplasia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The efficacy and safety of the combination of tamsulosin and tadalafil in men with lower urinary tract symptoms due to benign prostatic hyperplasia and Erectile Dysfunction: a randomized, double blinded, parallel design, active controlled, multi-center, phase 3 clinical trial
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Visit1
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tamsulosin 0.2mg and Tadalafil 5mg
Drug: Tamsulosin 0.2mg · Drug: Tadalafil 5mg
placebo for Tamsulosin 0.2mg and Tadalafil 5mg
Drug: Tadalafil 5mg · Drug: Placebo for Tamsulosin
The change of total IPSS(International prostate symptom score)
Time frame: From baseline at week 12
The change of IIEF-EF(International Index of Erectile Function sum of questions-Erectile function) domain
Time frame: From baseline at week 12
The change of total IPSS(International prostate symptom score)
Time frame: From baseline at week 4,8
The change of total IPSS(International prostate symptom score) sub score (storage, voiding)
Time frame: From baseline at week 4,8 and 12
The change of IPSS(International prostate symptom score) QoL(Quality of Life)
Time frame: From baseline at week 4,8 and 12
The change of Qmax(maximum urinary flow rate)
Time frame: From baseline at week 4,8 and 12
The change of PVR(Post Void Residual Volume)
Time frame: From baseline at week 4,8 and 12
PGIC(Patient Global Impression of change) score
Time frame: At week 12
CGIC(Clinician Global Impression of change) score
Time frame: At week 12
The change of IIEF (International Index of Erectile Function sum of questions) total score
Time frame: From baseline at week 4,8 and 12
The change of IIEF-IS(International Index of Erectile Function sum of questions-Intercourse satisfaction) domain score measured by IIEF question number 6~8
Time frame: From baseline at week 4,8 and 12
The change of OS(Overall satisfaction) domain score measured by IIEF question number13 and 14
Time frame: From baseline at week 4,8 and 12
The change of OF(Orgasmic function) domain score measured by IIEF question number 9 and 10)
Time frame: From baseline at week 4,8 and 12
The change of IIEF-EF domain(International Index of Erectile Function sum of questions-Erectile function) score measured by IIEF question number 1~5 and 15
Time frame: From baseline at week 4,8
The change of IIEF(International Index of Erectile Function) score about questions number 3 and 4
Time frame: From baseline at week 12
The percentage of patients who have more than 4 point about IIEF questions number 3 and 4
Time frame: From baseline at week 12
The percentage of patients who have increased score about IIEF questions number 3 and 4(at least 1 point) compared to the baseline
Time frame: From baseline at week 12
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Mar 2016, a primary completion of Mar 2017 and a completion of Mar 2017. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tamsulosin
IlDong Pharmaceutical Co Ltd →